Tevogen Bio Holdings Inc.
TVGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTevogen Bio Holdings Inc. operates in the Biotechnology space. Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company carries a $47.8M market cap, placing it firmly in the micro-cap category. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Market Cap
$47.8M
Beta
0.19
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-6.29
EPS (Fwd)
—
ROE
—
ROA
-297.4%
Cash
$1.1M
Total Debt
$9.4M
Free CF
-$3.1M
52W Change
-83.4%
Annual Financials
Cash vs Debt
Where TVGN stands vs its 150-day and 200-day moving averages
As of the August 17, 2026 close, TVGN finished 22.55% below its 150-day moving average ($8.87) and 43.22% below its 200-day moving average ($12.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TVGN overbought or oversold?
At the August 17, 2026 close, TVGN's RSI(14) was 71.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, TVGN has $1.1M in cash with $9.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$3.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
With a beta below 0.7, Tevogen Bio Holdings Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Tevogen Bio Holdings Inc.'s trajectory.